Full Text
Cost Effectiveness of Pembrolizumab (Keytruda®) Versus Ipilimumab in Patients with Advanced Melanoma in the United States

Abstract

Authors

J Wang J Pellissier R Xu FX Liu K Stevinson B Chmielowski

Back to Volume 19, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×